SEVERITY OF ILLNESS AMONG PERSONS WITH MULTIPLE SCLEROSIS: AN ANALYSIS OF COST QUINTILES

N.L. Kleinman,¹ K. Rajagopalan,² R. A. Brook,³ A.K. Melkonian¹


1Human Capital Management Services (HCMS) Group, Cheyenne, WY, USA; 2Biogen Idec, Inc., Cambridge, MA, USA; 3The JeSTARx Group, Newfoundland, NJ, USA

INTRODUCTION:

- ▶ Multiple sclerosis (MS) is an acquired, inflammatory and immune mediated disorder of the central nervous system characterized by inflammation, demyelination and degeneration of axonal neurons that affects more than 2 million people worldwide and estimates range from 350,000 to 440,000 in the United States.^{1,2}
- In clinical studies, MS severity is often measured by the Expanded Disability Status Scale (EDSS),3 the MS Functional Composite Measure (MSFC),4 or the Functional Assessment of Multiple Sclerosis (FAMS).5
- ▶ Unfortunately, most administrative claims data do not contain severity measures.
- ▶ We explored whether disease-specific cost (DSC) quintiles may be indicative of disease severity in an examination of MS. These quintiles were based on the Pareto Principle:
- Vilfredo Pareto was an economist who is credited with establishing what is now widely known as the Pareto Principle or 80/20 rule that costs or resources will be maldistributed within a population such that 20% of the population consumes 80% of the costs.
- ▶ As a proxy for severity of illness, we wanted to test what percent of the population incurred the top 20% of disease specific costs.

METHODOLOGY:

- ▶ The employees included in this research project came from the Human Capital Management Services Research Reference Database (HCMS RRDb).
- ▶ Data for these employees come from multiple large employers that are widely dispersed throughout the United States and




- represent the retail, service, manufacturing, and financial
- ► Employees with Multiple Sclerosis were identified with a primary, secondary, or tertiary diagnosis using the International Classification of Diseases, 9th Revision diagnostic codes for Multiple Sclerosis (ICD-9=340.xx).
- Annual Disease-Specific Costs (DSC) were calculated as the sum of the:
- Disease-Specific Medical Costs for services associated with the disease-specific ICD-9 codes and the
- Disease-Specific Prescription Costs for outpatient diseasemodifying therapies (DMTs):
- Avonex [IFN-β1a IM];
- ► Betaseron [IFN-β1b];
- ► Copaxone [glatiramer acetate]; and
- ▶ Rebif [IFN-β1a SC].
- ▶ Employees with MS were rank ordered into 5 cost guintiles based on DSC (20% of DSC in each) ranging from lowest to highest cost.
- Pairwise differences in the quintile distributions were assessed using Chi-squared (χ²) tests.

RESULTS:

- ► Total Employees with MS: 765
- ► Therapy utilization by Quintile (**Table 1**).
- Looking at only the MS Specific Medical and MS and Other Prescription Drug Costs (Figure 1) indicates possible comorbid issues in Quintile 1.

Figure 2: MS-Specific and Other Condition Medical and Prescription Cost by Quintile



- ► The MS Specific and Other Condition Medical and Prescription Drug Costs by Quintile are presented in Figure 2.
- ► Indirect Costs of Employees with MS by Quintile (Table 2).
- Productivity of Employees with MS by Quintile (Table 3).

CONCLUSIONS:

- ► Disease-Specific Costs are extremely maldistributed—the top Quintile of expenditures was incurred by only 4.4% of the population.
- ► Employees in the top Quintile had the highest total health benefit costs.
- ► Employees in the lowest Quintile were least likely to receive MS-specific prescription drug therapies.
- These comparisons may suggest that cost quintiles could be indicative of severity in MS. Further investigation is warranted over an extended period of time to confirm this relationship.
- Untreated Employees with MS in Quintile 1 (the majority of Quintile 1) may have higher comorbid medical costs than with those receiving proper MS treatment; possibly due to symptomatic treatment of comorbid symptoms than treating the underlying disease. These results may be suggestive of the important need for early and appropriate treatment of MS with DMTs and warrants further investigation.

Quintile 1 (N=550) Quintile 2 (N=68) Quintile 3 (N=61) Quintile 3 (N=52)	Quintile 5	Significant Quintile Differences ¹
	(14-0-1)	Diliciciicos
% of Quintile using any 18.0% 100.0% 100.0% 100.0% 100.0%	91.2%	all>1, 2>5, 3>5, 4>5

lable 2. Indirect Costs of Employees with MS by Quintile (during the year following each person's index date ¹) Total Employees with MS						
	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5	Significant Quintile

(3.3)	· .					
	Quintile 1 (N=550)	Quintile 2 (N=68)	Quintile 3 (N=61)	Quintile 4 (N=52)	Quintile 5 (N=34)	Significant Quintile Differences ²
Workers' Compensation Metrics (Eligible N)	(N=520)	(N=59)	(N=59)	(N=52)	(N=33)	
Workers' Compensation Medical Cost	\$298	\$80	\$62	\$0	\$0	4<1, 5<1
Workers' Compensation Disability Cost	\$288	\$59	\$0	\$0	\$0	
Sick Leave Metric (Eligible N)	(N=266)	(N=29)	(N=27)	(N=27)	(N=9)	
Sick Leave Cost	\$636	\$712	\$837	\$1,862	\$1,237	
Short-Term Disability Metric (Eligible N)	(N=298)	(N=27)	(N=34)	(N=36)	(N=21)	
Short-Term Disability Cost	\$1,304	\$67	\$487	\$1,590	\$1,508	2<1
Long-Term Disability Metric (Eligible N)	(N=420)	(N=49)	(N=48)	(N=41)	(N=23)	
Long-Term Disability Cost	\$366	\$0	\$314	\$1,453	\$0	

For employees with treatment, the index date is the date of the first MS prescription. For those without, it is the average date from those treated.

Table 3. Productivity of Employees with MS by Quintile (during the year following each person's index date¹) Total Employees with MS: 765

	(,		
		Quintile 1 (N=550)	Quintile 2 (N=68)	Quintile 3 (N=61)	Quintile 4 (N=52)	Quintile 5 (N=34)	
	Productivity Metrics (Eligible N)	(N=24)	(N=3)	(N=2)	(N=0)	(N=1)	
	Units processed / hour worked	15.92	16.50	14.54		6.40	
	Units processed / year	23,248	29,009	22,832		7,942	

² Differences are considered significant if P < 0.05

None of the productivity differences between cohorts were significant.

References

- 1 Joy JE, Johnston RB, eds. Multiple Sclerosis: Current Status and Strategies for the Future Committee on Multiple Sclerosis. Washington, DC: National Academy Press; 2004. Available in part at: http://books.nap.edu/ execsumm pdf/10031.pdf, Accessed March 3, 2008
- ² Just the Facts. Frequently asked questions about MS and the National MS Society. Available at http://www.nationalmssociety.org/about-multiple-sclerosis/FAQs-about-MS/index.aspx#top
- ³ Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52.
- Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes
- ⁶ Cella DF, Dineen K, Arnason B, Reder A, Webster KA, karabatsos G, Chang C, Lloyd S, Steward J, Stefoski D. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996

NOTES

Brook RA, Rajagopalan K, Kleinman NL, Melkonian AK. Prevalence and costs of Comorbidities among persons with and without Multiple Sclerosis: An Analysis of the AHRQ Major And Specific Diagnostic Categories. *Value Health*. 2008; 11(3).

SEVERITY OF ILLNESS AMONG PERSONS WITH MULTIPLE SCLEROSIS: AN ANALYSIS OF COST QUINTILES

N.L. Kleinman,¹ K. Rajagopalan,² R. A. Brook,³ A.K. Melkonian¹

¹Human Capital Management Services (HCMS) Group, Cheyenne, WY, USA; ²Biogen Idec, Inc., Cambridge, MA, USA; ³The JeSTARx Group, Newfoundland, NJ, USA

ABSTRACT

OBJECTIVES: Retrospective claims databases often lack measures of disease severity. As a proxy for severity of illness, a quintile analysis of employees with multiple sclerosis (MS) was conducted.

METHODS: A US healthcare claims database from 2001-2007 was used to identify employees with MS (ICD-9 code=340.XX). Subjects were followed for 1 year after their index dates, based on the first disease-modifying therapy (DMT) prescription (IFN -1a [SC or IM], IFN -1b, or glatiramer acetate) or for those with no therapy the average date of those treated. MS-specific medical costs were defined as total claims costs with primary ICD-9=340.xx. MS-specific drug costs were defined as all DMT expenditures. Employees were rank ordered by MS-specific (medical and drug) costs and assigned to cost quintiles.

RESULTS: 765 employees with MS were analyzed, and 71.9% (N=550) with lowest cost (Quintile 1) incurred \$1,593 in MS-specific (medical and drug) costs/employee. Quintiles 2-4 (8.9%, 8.0%, and 6.8% of the population, respectively) incurred MS-specific costs of \$12,830, \$14,348, and \$17,028/employee, respectively. Finally, employees in Quintile 5 (highest cost, 4.4%, N=34) incurred MS-specific costs of \$26,048/employee. Only 18% of Quintile 1 had a DMT, all subjects in Quintiles 2-4 used DMTs, and 8.8% of Quintile 5 used no DMTs. Interestingly, the "other conditions" costs/employee were higher in higher cost quintiles, and Quintile 5 non-MS drug costs/employee were 6.1—8.6 times higher than Quintiles 1-4. Quintile 5 was only 47.1% female, while the other quintiles were >60% female. Average ages were similar between quintiles ranging from 40.5 to 40.6 years. Although not used for quintile assignments, indirect costs were generally higher in the more expensive quintiles.

CONCLUSIONS: Wide variation in MS-specific and non-specific costs exists among employees with MS. However, patients in the highest cost quintile are also possibly the most severe, suffered from multiple conditions and received other drug treatments. Further investigation is needed to understand the impact of comorbid conditions on severity.